HCV and Progression of HIV and HAART Response in Women
女性 HCV 和 HIV 进展以及 HAART 反应
基本信息
- 批准号:6892041
- 负责人:
- 金额:$ 90.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-06-01 至 2007-05-31
- 项目状态:已结题
- 来源:
- 关键词:AIDSAIDS therapyHIV infectionsHerpesviridae diseaseT cell receptorT lymphocyteantigen presenting cellantiviral agentsclinical researchcombination chemotherapycytomegalovirusfemalegenotypeheterogeneous nuclear RNAhuman immunodeficiency virus 1human subjecthuman therapy evaluationinterferon gammaliver cellslongitudinal human studymicroorganism interactionnucleic acid sequencepatient oriented researchpolymerase chain reactionsecondary infectionserumsingle strand conformation polymorphismvirus loadvirus replication
项目摘要
DESCRIPTION: (provided by applicant) Overview: Recent evidence indicates that
co-infection with HCV may negatively impact HIV disease progression and
response to HAART. Almost 40 percent) of women enrolled in the Women's
Interagency HIV Study (WMS) are co-infected with HCV affording a unique
opportunity to study the effect of HCV on disease progression and response to
HAART. We propose a two-part study that will consist of both retrospective and
prospective evaluations utilizing repository samples and clinical information
from 368 HIV+/HCV+ and 650 HIV+/HCV- women in WMS and 30 newly identified
HAAKT-naive women. Hypotheses: We hypothesize that: i) HIV-1 infected women who
are co-infected with HCV will have increased H N RNA levels, and more rapid CD4
decline and progression to AIDS than women who are HCV uninfected, and ii)
after HAART, HCV viremia and extrahepatic replication will impair viral
response to therapy and immune recovery. Aims: To address hypothesis I , we
will determine the relationship between HCV infection and disease progression
based on epidemiologic, clinical, virologic, and immunologic features of women
in WIHS. Specifically we will: i) study the effect of plasma HCV RNA,
quasispecies diversity, and genotype on HIV disease progression; ii) assess for
extrahepatic replication in PBMCs and determine its relationship with HIV RNA
level and stage of HIV disease; iii) establish if HCV viremia and extrahepatic
replication are associated with immune activation, alterations in naive and
memory CD4 and CD8 cells, and thymic output. To address hypothesis 2, we will:
i) assess if plasma HCV RNA, genotype, quasispecies diversity and extrahepatic
replication in PBMCs prior to HAART influence virologic and immunologic
response after HAART; and ii) evaluate for early changes in HIV and HCV RNA and
immune recovery following HAART in a group of intensively followed women. These
studies will contribute to our understanding of the interaction of these
viruses in a clinical setting and help to delineate populations of women who
may benefit from specific antiviral therapies.
描述:(由申请人提供)概述:最近的证据表明,
与HCV合并感染可能对HIV疾病进展产生负面影响,
对HAART的回应近40%)的妇女参加了妇女
机构间HIV研究(WMS)与HCV共感染,
有机会研究HCV对疾病进展和对
HAART。我们提出了一个两部分的研究,将包括回顾性和
利用储存库样本和临床信息进行前瞻性评价
来自WMS的368名HIV+/HCV+和650名HIV+/HCV-妇女以及30名新发现的
HAAKT天真的女人。假设:我们假设:i)感染HIV-1的妇女,
同时感染HCV的人,其H N RNA水平会增加,
与未感染HCV的女性相比,下降并进展为艾滋病,以及ii)
HAART后,HCV病毒血症和肝外复制将损害病毒
对治疗的反应和免疫恢复。目的:为了解决假设一,我们
将确定HCV感染和疾病进展之间的关系
基于女性的流行病学、临床、病毒学和免疫学特征
在WIHS。具体而言,我们将:i)研究血浆HCV RNA的作用,
准种多样性和基因型对HIV疾病进展的影响; ii)评估
PBMCs中的肝外复制,并确定其与HIV RNA的关系
HIV疾病的水平和阶段; iii)确定HCV病毒血症和肝外
复制与免疫激活,幼稚和
记忆CD 4和CD 8细胞以及胸腺输出。为了解决假设2,我们将:
i)评估血浆HCV RNA、基因型、准种多样性和肝外
HAART前PBMC中的复制影响病毒学和免疫学
ii)评估HIV和HCV RNA的早期变化,以及
在一组集中随访的妇女中,HAART后免疫恢复。这些
研究将有助于我们理解这些因素之间的相互作用。
病毒在临床环境中的作用,并有助于描述
可能受益于特定的抗病毒治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrea A.Z. Kovacs其他文献
Andrea A.Z. Kovacs的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrea A.Z. Kovacs', 18)}}的其他基金
Long-term Effects of IDU, HIV, HCV and the Impact of HCV Cure on Immune Activation and Liver Fibrosis in Aging Women
IDU、HIV、HCV 的长期影响以及 HCV 治愈对老年女性免疫激活和肝纤维化的影响
- 批准号:
9355485 - 财政年份:2017
- 资助金额:
$ 90.54万 - 项目类别:
HCV and HIV Progression in Women on HAART
接受 HAART 治疗的女性 HCV 和 HIV 进展情况
- 批准号:
8143231 - 财政年份:2010
- 资助金额:
$ 90.54万 - 项目类别:
HCV and HIV Progression in Women on HAART
接受 HAART 治疗的女性 HCV 和 HIV 进展情况
- 批准号:
7930347 - 财政年份:2009
- 资助金额:
$ 90.54万 - 项目类别:
AN OPEN-LABEL STUDY OF A ONCE DAILY DOSE OF EMTRICITABINE IN COMBINATION WITH
每日一次剂量的恩曲他滨与以下药物联合的开放标签研究
- 批准号:
7368197 - 财政年份:2005
- 资助金额:
$ 90.54万 - 项目类别:
AN OPEN-LABEL STUDY OF A ONCE DAILY DOSE OF EMTRICITABINE IN COMBINATION WITH
每日一次剂量的恩曲他滨与以下药物联用的开放标签研究
- 批准号:
7200000 - 财政年份:2004
- 资助金额:
$ 90.54万 - 项目类别:
PREVALENCE OF MORPHOLOGIC AND METABOLIC ABNORMALITIES IN HIV INFECTED
HIV 感染者形态和代谢异常的患病率
- 批准号:
7200032 - 财政年份:2004
- 资助金额:
$ 90.54万 - 项目类别:
ACTG 265: A PHASE I/II STUDY OF SAFETY & IMMUNOGENICITY OF LIVE-ATTENUATED
ACTG 265:I/II 期安全性研究
- 批准号:
7199983 - 财政年份:2004
- 资助金额:
$ 90.54万 - 项目类别:
ACTG 265: A PHASE I/II STUDY OF SAFETY & IMMUNOGENICITY OF LIVE-ATTENUATED
ACTG 265:I/II 期安全性研究
- 批准号:
7040145 - 财政年份:2003
- 资助金额:
$ 90.54万 - 项目类别:
OPEN-LABEL STUDY OF A ONCE DAILY DOSE OF EMTRICITABINE
每日一次剂量恩曲他滨的开放标签研究
- 批准号:
7040170 - 财政年份:2003
- 资助金额:
$ 90.54万 - 项目类别:
HCV and Progression of HIV and HAART Response in Women
女性 HCV 和 HIV 进展以及 HAART 反应
- 批准号:
6627831 - 财政年份:2002
- 资助金额:
$ 90.54万 - 项目类别:
相似海外基金
Basic and applied study on AIDS-therapy using hybrid liposomes
混合脂质体治疗艾滋病的基础与应用研究
- 批准号:
24656509 - 财政年份:2012
- 资助金额:
$ 90.54万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
SIV MODEL FOR MULTI DRUG RESISTANCE TO AIDS THERAPY
艾滋病治疗多重耐药性的 SIV 模型
- 批准号:
6940442 - 财政年份:2003
- 资助金额:
$ 90.54万 - 项目类别:
RT-SHIV MODEL FOR RESISTANCE TO AIDS THERAPY
艾滋病治疗抵抗力的 RT-SHIV 模型
- 批准号:
6940441 - 财政年份:2003
- 资助金额:
$ 90.54万 - 项目类别:
Mitochondrial Toxicity of Antiviral Nucleosides in AIDS Therapy
艾滋病治疗中抗病毒核苷的线粒体毒性
- 批准号:
7421121 - 财政年份:2002
- 资助金额:
$ 90.54万 - 项目类别:
Targeted Manipulation of Stem Cells for AIDS Therapy
干细胞的靶向操作用于艾滋病治疗
- 批准号:
7479315 - 财政年份:2001
- 资助金额:
$ 90.54万 - 项目类别:
TARGETED MANIPULATION OF STEM CELLS FOR AIDS THERAPY
干细胞的靶向操作用于艾滋病治疗
- 批准号:
6312501 - 财政年份:2001
- 资助金额:
$ 90.54万 - 项目类别:
TARGETED MANIPULATION OF STEM CELLS FOR AIDS THERAPY
干细胞的靶向操作用于艾滋病治疗
- 批准号:
6499098 - 财政年份:2001
- 资助金额:
$ 90.54万 - 项目类别:
Targeted Manipulation of Stem Cells for AIDS Therapy
干细胞的靶向操作用于艾滋病治疗
- 批准号:
7666728 - 财政年份:2001
- 资助金额:
$ 90.54万 - 项目类别:
TARGETED MANIPULATION OF STEM CELLS FOR AIDS THERAPY
干细胞的靶向操作用于艾滋病治疗
- 批准号:
6708893 - 财政年份:2001
- 资助金额:
$ 90.54万 - 项目类别:
TARGETED MANIPULATION OF STEM CELLS FOR AIDS THERAPY
干细胞的靶向操作用于艾滋病治疗
- 批准号:
6849724 - 财政年份:2001
- 资助金额:
$ 90.54万 - 项目类别: